Table 2. Temporal trends of SP drug resistance haplotypes from 2012 to 2017 by study period.

	pfdhfr		pfdhps	2012–2013	2016–2017	Total	P-value a
				n = 95 (%)	n =128 (%)	n=223 (%)
N51I	C59R	S108N	A437G
I	R	N	G/A	50 (52.6)	101(79)	151(67.7)	<0.0001
N	R	N	G	10 (10.5)	8 (6.3)	18 (8.1)	0.321
I	R	S	G	8 (8.4)	2 (1.6)	10 (4.5)	0.020
I	C	N	G	7 (7.4)	12 (9.4)	19 (8.5)	0.637
N	R	S	G	5 (5.3)	2 (1.6)	7(3.1)	0.140
I	C	N	A	4 (4.2)	0 (0)	4 (1.8)	0.032
N	C	N	G	3 (3.2)	1 (0.8)	4 (1.8)	0.315
N	R	N	A	3 (3.2)	1 (0.8)	4 (1.8)	0.315

Note: Numbers include only isolates that were successfully genotyped for all the four point mutations in pfdhfr and pfdhps.

Each haplotype has mutant amino acids shown in bold. ^aP-value based on Exact chi-square test